ecrin-mdr-crcClinical2016Colorectal CancerColorectal NeoplasmsColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2205561SwedenNorwayFinlandDenmark4AspirinPI3K signaling pathwayECRIN MDRRecruitingfalseAdjuvant Low Dose Aspirin in Colorectal CancerALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.2016-04-152205561NCT02647099